These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 15206867

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Zorzet S, Sava G.
    J Med Chem; 2004 Feb 26; 47(5):1110-21. PubMed ID: 14971891
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M, Reisner E, Hartinger CG, Eichinger R, Semenova O, Timerbaev AR, Jakupec MA, Arion VB, Keppler BK.
    J Med Chem; 2007 May 03; 50(9):2185-93. PubMed ID: 17402720
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
    Tan C, Hu S, Liu J, Ji L.
    Eur J Med Chem; 2011 May 03; 46(5):1555-63. PubMed ID: 21354673
    [Abstract] [Full Text] [Related]

  • 5. Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)].
    Mura P, Piccioli F, Gabbiani C, Camalli M, Messori L.
    Inorg Chem; 2005 Jul 11; 44(14):4897-9. PubMed ID: 15998012
    [Abstract] [Full Text] [Related]

  • 6. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E, Arion VB, Guedes da Silva MF, Lichtenecker R, Eichinger A, Keppler BK, Kukushkin VY, Pombeiro AJ.
    Inorg Chem; 2004 Nov 01; 43(22):7083-93. PubMed ID: 15500346
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV, Robertazzi A, Magistrato A, Ruggerone P, Carloni P.
    J Phys Chem B; 2008 Apr 10; 112(14):4401-9. PubMed ID: 18348562
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M, Baracco S, Cassino C, Zanello P, Osella D.
    Dalton Trans; 2004 Aug 07; (15):2347-51. PubMed ID: 15278129
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
    Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2004 Jul 07; 54(1):71-8. PubMed ID: 15034754
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
    Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchietto M, Zorzet S, Sava G.
    Int J Oncol; 2002 Dec 07; 21(6):1331-8. PubMed ID: 12429985
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R, Tamasi G, Defazio S, Corsini M, Zanello P, Messori L, Marcon G, Piccioli F, Orioli P.
    Inorg Chem; 2003 Dec 01; 42(24):8038-52. PubMed ID: 14632524
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ruthenium antimetastatic agents.
    Alessio E, Mestroni G, Bergamo A, Sava G.
    Curr Top Med Chem; 2004 Dec 01; 4(15):1525-35. PubMed ID: 15579094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.